Literature DB >> 26657613

Targeting substance P and relaxin: A future combination therapy approach for heart failure?

Scott P Levick1, Giselle C Meléndez2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26657613     DOI: 10.1016/j.ijcard.2015.11.157

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  2 in total

1.  Direct activation of tachykinin receptors within baroreflex afferent pathway and neurocontrol of blood pressure regulation.

Authors:  Mei Yuan; Mei-Na Ma; Ting-Yu Wang; Yan Feng; Pei Chen; Chao He; Sijie Liu; Yun-Xia Guo; Yue Wang; Yao Fan; Lu-Qi Wang; Xiao-Qiang E; Guo-Fen Qiao; Bai-Yan Li
Journal:  CNS Neurosci Ther       Date:  2018-06-13       Impact factor: 5.243

2.  Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failure.

Authors:  Henrike Arfsten; Georg Goliasch; Philipp E Bartko; Suriya Prausmüller; Georg Spinka; Anna Cho; Johannes Novak; Julia Mascherbauer; Helmuth Haslacher; Guido Strunk; Martin Hülsmann; Noemi Pavo
Journal:  ESC Heart Fail       Date:  2021-03-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.